About ImmuTarget

Meet Our Team

Xiaoxia Wang

Xiaoxia Wang, B.Sc. - Principal Scientist

Xiaoxia Wang brings over 20 years of production experience to the team. She began her career in tetramer production at the University of British Columbia, where she focused on tetramer production, and has spent the past 7 years at the Fred Hutch Cancer Center, refining her expertise. Xiaoxia has developed a production protocol, which significantly enhances efficiency compared to traditional methods, allowing for faster production with less labor. Her commitment to continuous improvement drives her to innovate and optimize her protocols. With her extensive industry knowledge and deep understanding of buyer needs and market demands, Xiaoxia offers invaluable insights to our team.

Dr. Tan

Rusung Tan, M.D Ph.D. - Scientific Advisor

Dr. Tan is a Professor Emeritus of Pathology and Laboratory Medicine at the University of British Columbia and currently serves as Chief of Pathology at The View Hospital in Doha, Qatar, as well as a Clinical Professor of Laboratory Medicine and Pathology at Qatar University. He previously held roles as Executive Director of Foundational Clinical Services and founding Chief of Pathology at Sidra Medicine in Qatar, and as Professor of Pathology & Laboratory Medicine at Weill Cornell Medicine, Qatar.

Our Mission

At ImmuTarget, our mission is to help you advance your research and development by offering affordable, high-quality, and high-purity MHC class I tetramers and monomers across a broad range of human and murine heavy chains. We provide many options, including human A*0201, A*1101, A*2301, A*2402, B*0702, B*5701, C*0401, murine H2-Kb, H2-Kd, H2-Db, H2-Dd, as well as non-classical MHC molecules like HLA-G ( ). Our commitment is to empower researchers worldwide in their quest to better understand the immune system and develop novel immunotherapies, by making these critical tools accessible and affordable.

Tetramers

MHC class I tetramers, introduced by John Altman and Mark Davis in 1996, are complexes consisting of four biotinylated MHC class I monomers linked by streptavidin and tagged with a fluorescent marker. This tetramerization of the peptide-MHC (pMHC) complex significantly enhances pMHC–TCR avidity, facilitating stable cell surface staining of cytotoxic T lymphocytes (CTLs). Primarily used in flow cytometry, MHC class I tetramers are essential for visualizing, tracking, and enumerating antigen-specific CD8+ CTLs in various contexts, including infection[1,2], autoimmunity[3,4], cancer[5], and allergy[6]. They are also valuable for identifying novel MHC class I epitopes using in silico predicted candidate peptides, or for studying and tracking cancer-specific CTLs with neoantigen-derived peptides[7,8]. Additionally, monomeric pMHC complexes are available in milligram quantities for crystallization studies[9].

Additional Products and Applications

In addition to traditional tetramers, ImmuTarget offers custom solutions for advanced T cell enrichment and the identification of multiple peptide-specific T cell populations, as well as neoantigen tetramers for cancer immunodiagnostics and immunotherapy. Please contact us to discuss your specific needs, and we can work with you to designa a solution.

We can also create made-to-order tetramers for MHC class I tetramers loaded with neoantigen peptides. These can be used to effectively track and analyze tumor-specific T cell populations in cancer patients and is an instrumental tool for advancing the study of cancer vaccines and immunotherapies, especially for solid tumors.

References

  1. Altman, J. D., et al. (1996). Phenotypic analysis of antigen-specific T lymphocytes. Science, 274(5284), 94-96.
  2. Klenerman, P., Cerundolo, V., & Dunbar, P. R. (2002). Tracking T cells with tetramers: new tales from new tools. Nature Reviews Immunology, 2(4), 263-272.
  3. Unanue, E. R., Ferris, S. T., & Carrero, J. A. (2016). The role of islet antigen presenting cells and the presentation of insulin in the initiation of autoimmune diabetes in the NOD mouse. Immunological Reviews, 272(1), 183-201.
  4. James, E. A., et al. (2014). Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis & Rheumatology, 66(7), 1712-1722.
  5. Bentzen, A. K., & Hadrup, S. R. (2017). Evolution of MHC-based technologies used for detection of antigen-responsive T cells. Cancer Immunology, Immunotherapy, 66(5), 657-666.
  6. DeLong, J. H., et al. (2011). Ara h 1-reactive T cells in individuals with peanut allergy. Journal of Allergy and Clinical Immunology, 127(5), 1211-1218.e3.
  7. Tran, E., et al. (2016). T-cell transfer therapy targeting mutant KRAS in cancer. New England Journal of Medicine, 375(23), 2255-2262.
  8. Balachandran, V. P., et al. (2017). Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551(7681), 512-516.
  9. Wright, K.M., et al. (2023) Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. Nat Commun 14, 5063.